The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Optimal Timing of Surgery After Chemoradiation for Advanced Rectal Cancer: Preliminary Results of a Multicenter, Nonrandomized Phase II Prospective Trial
Open accessAbstract
OBJECTIVE: To determine whether extending the interval between chemoradiation (CRT) and surgery, and administering additional chemotherapy during the waiting period has an impact on tumor response, CRT-related toxicity and surgical complications in patients with advanced rectal cancer. BACKGROUND: Locally advanced rectal cancer is usually treated with preoperative CRT followed by surgery approximately 6 weeks later. The Timing of Rectal Cancer Response to Chemoradiation Consortium designed a prospective, multicenter, Phase II clinical trial to investigate extending the interval between CRT and surgery, and administering additional chemotherapy during the waiting period. Here, we present preliminary results of this trial, reporting the tumor response, CRT-related toxicity and surgical complications. METHODS: Stage II and III rectal cancer patients were treated concurrently with 5-Fluorouracil (FU) and radiation for 5 to 6 weeks. Patients in study group (SG) 1 underwent total mesorectal excision (TME) 6 weeks later. Patients in SG2 with evidence of a clinical response 4 weeks after CRT received 2 cycles of modified FOLFOX-6 (mFOLFOX-6) followed by TME 3 to 5 weeks later. Tumor response, CRT-related toxicity and surgical complications were recorded. RESULTS: One hundred and forty-four patients were accrued. One hundred and thirty-six (66, SG1; 70, SG2) were evaluated for CRT-related toxicity. One hundred and twenty-seven (60, SG1; 67, SG2) were assessed for tumor response and surgical complications. A similar proportion of patients completed CRT per protocol in both SGs, but the cumulative dose of sensitizing 5-FU and radiation was higher in SG2. CRT-related toxicity was comparable between SGs. Average time from CRT-to-surgery was 6 (SG1) and 11 weeks (SG2). Pathologic complete response (pCR) was 18% (SG1) and 25% (SG2). Postoperative complications were similar between SGs. CONCLUSIONS: Intense neoadjuvant therapy consisting of CRT followed by additional chemotherapy (mFOLFOX-6), and delaying surgery may result in a modest increase in pCR rate without increasing complications in patients undergoing TME for locally advanced rectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
The Clavien-Dindo Classification of Surgical Complications: Five-Year Experience
Clavien, P. A., Barkun, J., de Oliveira, M. L., Vauthey, J. N., Dindo, D., Schulick, R. D., de Santibañes, E., Pekolj, J., Slankamenac, K., Bassi, C., et al. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181b13ca2 · Cited by 11,482
Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040694 · Cited by 6,050
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Maas, M., Nelemans, P. J., Valentini, V., Das, P., Rödel, C., Kuo, L.-J., Calvo, F. A., García-Aguilar, J., Glynne-Jones, R., Haustermans, K., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70172-8 · Cited by 1,945
Francois, Y., Nemoz, C. J., Baulieux, J., Vignal, J., Grandjean, J.-P., Partensky, C., Souquet, J. C., Adeleine, P., & Gerard, J.-P. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2396 · Cited by 815
RECIST revisited: A review of validation studies on tumour assessment
Therasse, P., Eisenhauer, E. A., & Verweij, J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.01.026 · Cited by 422
Kalady, M. F., de Campos-Lobato, L. F., Stocchi, L., Geisler, D. P., Dietz, D., Lavery, I. C., & Fazio, V. W. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181b91e63 · Cited by 386
Chua, Y. J., Barbachano, Y., Cunningham, D., Oates, J. R., Brown, G., Wotherspoon, A., Tait, D., Massey, A., Tebbutt, N. C., & Chau, I. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70381-x · Cited by 319
Tulchinsky, H., Shmueli, E., Figer, A., Klausner, J. M., & Rabau, M. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9892-3 · Cited by 304
Moore, H. G., Gittleman, A. E., Minsky, B. D., Wong, D., Paty, P. B., Weiser, M., Temple, L., Saltz, L., Shia, J., & Guillem, J. G. (2004) · Diseases of the Colon & Rectum · doi:10.1007/s10350-003-0062-1 · Cited by 258
Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer
O'Neill, B. D., Brown, G., Heald, R., Cunningham, D., & Tait, D. M. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70202-4 · Cited by 214
Habr-Gama, A., Perez, R. O., Proscurshim, I., Nunes dos Santos, R. M., Kiss, D., Gama-Rodrigues, J., & Cecconello, I. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.11.035 · Cited by 211
Kerr, S., Norton, S., & Glynne‐Jones, R. (2008) · British journal of surgery · doi:10.1002/bjs.6377 · Cited by 137
Optimal Surgery Time After Preoperative Chemoradiotherapy for Locally Advanced Rectal Cancers
Lim, S., Choi, H. S., Jeong, S., Kim, D. Y., Jung, K. H., Hong, Y. S., Chang, H. J., & Park, J. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e31817fc2a0 · Cited by 123
Stein, D. E., Mahmoud, N. N., Anne, P. R., Rose, D. G., Isenberg, G. A., Goldstein, S. D., Mitchell, E., & Fry, R. D. (2003) · Diseases of the Colon & Rectum · doi:10.1007/s10350-004-6579-0 · Cited by 118
Lyons Oncology Group, Gléhen, O., Chapet, O., Adham, M., Nemoz, J. C., & Gérard, J. (2003) · British journal of surgery · doi:10.1002/bjs.4162 · Cited by 107
Koeberle, D., Burkhard, R., von Moos, R., Winterhalder, R., Hess, V., Heitzmann, F., Ruhstaller, T., Terraciano, L. M., Neuweiler, J., Bieri, G., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604297 · Cited by 83
Wang, Y., Cummings, B., Catton, P. A., Dawson, L. A., Kim, J., Ringash, J. G., Wong, R. K. S., Yi, Q., & Brierley, J. D. (2005) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2005.09.001 · Cited by 82
Dolinsky, C. M., Mahmoud, N. N., Mick, R., Sun, W., Whittington, R. W., Solin, L. J., Haller, D., Giantonio, B. J., O’Dwyer, P., Rosato, E. F., et al. (2007) · Journal of Surgical Oncology · doi:10.1002/jso.20815 · Cited by 53
Negative influence of delayed surgery on survival after preoperative radiotherapy in rectal cancer
Supiot, S., Bennouna, J., Rio, E., Meurette, G., Bardet, É., Buecher, B., Dravet, F., Neel, J. ‐. L., Douillard, J.-Y., Mahé, M.-A., et al. (2006) · Colorectal Disease · doi:10.1111/j.1463-1318.2006.00990.x · Cited by 39
Cited by
Martin, S. T., Heneghan, H. M., & Winter, D. C. (2012) · British Journal of Surgery · doi:10.1002/bjs.8702 · Cited by 637
on behalf of the Rectal Cancer Consortium, Smith, J. J., Chow, O. S., Gollub, M. J., Nash, G. M., Temple, L. K., Weiser, M. R., Guillem, J. G., Paty, P. B., Avila, K., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1632-z · Cited by 391
Self-citationRadiation Therapy for Cervical Cancer: Executive Summary of an ASTRO Clinical Practice Guideline
Chino, J., Annunziata, C. M., Beriwal, S., Bradfield, L., Erickson, B. A., Fields, E. C., Fitch, K., Harkenrider, M. M., Holschneider, C. H., Kamrava, M., et al. (2020) · Practical Radiation Oncology · doi:10.1016/j.prro.2020.04.002 · Cited by 313
Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer
Sloothaak, D. A. M., Geijsen, D. E., van Leersum, N. J., Punt, C. J. A., Buskens, C. J., Bemelman, W. A., & Tanis, P. J. (2013) · British Journal of Surgery · doi:10.1002/bjs.9112 · Cited by 290
Glynne-Jones, R., & Hughes, R. (2012) · British Journal of Surgery · doi:10.1002/bjs.8732 · Cited by 256
Metadata
- Authors
- Garcia-Aguilar, J., Smith, D. D., Avila, K., Bergsland, E. K., Chu, P., & Krieg, R. M.
- Venue
- Annals of Surgery
- Published
- 2011-07
- Volume
- 254
- Issue
- 1
- Pages
- 97-102
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W1979238043
- Cited by
- 329
- References
- 21
- FWCI
- 12.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.